突破障碍：NEK2 抑制在多发性骨髓瘤治疗中大放异彩。
Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.
机构信息
Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Department of Internal Medicine 5, Haematology and Oncology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
出版信息
Cell Rep Med. 2023 Oct 17;4(10):101237. doi: 10.1016/j.xcrm.2023.101237.
Abstract
In their article, Cheng et al. reveal that NEK2 loss reshapes the tumor microenvironment, reducing tumor-associated macrophages and decreasing T cell exhaustion. They show that this ultimately favors the immune system's anti-cancer response in multiple myeloma.
摘要
程等人的文章揭示，NEK2 的缺失重塑了肿瘤微环境，减少了肿瘤相关巨噬细胞，并降低了 T 细胞衰竭。他们表明，这最终有利于免疫系统对多发性骨髓瘤的抗癌反应。
相似文献
1
Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.突破障碍：NEK2 抑制在多发性骨髓瘤治疗中大放异彩。
Cell Rep Med. 2023 Oct 17;4(10):101237. doi: 10.1016/j.xcrm.2023.101237.
2
Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment.NIMA 相关激酶 2 在多发性骨髓瘤中的过表达及其与硼替佐米治疗的疾病特征和预后的相关性。
J Clin Pharm Ther. 2022 Oct;47(10):1690-1697. doi: 10.1111/jcpt.13723. Epub 2022 Sep 10.
3
Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.基因异常和 NEK2 与 TP53 的相互作用加速多发性骨髓瘤的侵袭性。
Adv Sci (Weinh). 2022 Mar;9(9):e2104491. doi: 10.1002/advs.202104491. Epub 2022 Jan 27.
4
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.高表达的 NEK2 在髓系祖细胞中抑制多发性骨髓瘤中的 T 细胞免疫。
Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3.
5
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.NEK2 主要通过激活外排药物泵诱导耐药性，与骨髓瘤和其他癌症的不良预后相关。
Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001.
6
Nek2 is a novel regulator of B cell development and immunological response.Nek2是B细胞发育和免疫反应的新型调节因子。
Biomed Res Int. 2014;2014:621082. doi: 10.1155/2014/621082. Epub 2014 Nov 17.
7
NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase.NEK2通过调节丙酮酸激酶的剪接促进多发性骨髓瘤中的有氧糖酵解。
J Hematol Oncol. 2017 Jan 13;10(1):17. doi: 10.1186/s13045-017-0392-4.
8
NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer.NEK2 在非小细胞肺癌的肿瘤发生和肿瘤微环境中发挥积极作用。
Int J Biol Sci. 2021 May 11;17(8):1995-2008. doi: 10.7150/ijbs.59019. eCollection 2021.
9
NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.NEK2 通过稳定多发性骨髓瘤中的 Beclin-1 诱导自噬介导的硼替佐米耐药性。
Mol Oncol. 2020 Apr;14(4):763-778. doi: 10.1002/1878-0261.12641. Epub 2020 Jan 29.
10
NIMA related kinase 2 promotes gastric cancer cell proliferation ERK/MAPK signaling.NIMA 相关激酶 2 促进胃癌细胞增殖 ERK/MAPK 信号通路。
World J Gastroenterol. 2019 Jun 21;25(23):2898-2910. doi: 10.3748/wjg.v25.i23.2898.
引用本文的文献
1
NEK2 regulates B cell function and the severity of experimental autoimmune encephalomyelitis.NEK2调节B细胞功能及实验性自身免疫性脑脊髓炎的严重程度。
J Neuroinflammation. 2025 Jun 6;22(1):152. doi: 10.1186/s12974-025-03472-w.
2
Role of NEK2 in tumorigenesis and tumor progression.NEK2在肿瘤发生和肿瘤进展中的作用。
Trends Mol Med. 2025 Jan;31(1):79-93. doi: 10.1016/j.molmed.2024.07.013. Epub 2024 Aug 24.
3
The role of tumor-associated macrophages in tumor immune evasion.肿瘤相关巨噬细胞在肿瘤免疫逃逸中的作用。
J Cancer Res Clin Oncol. 2024 May 7;150(5):238. doi: 10.1007/s00432-024-05777-4.
本文引用的文献
1
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.高表达的 NEK2 在髓系祖细胞中抑制多发性骨髓瘤中的 T 细胞免疫。
Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3.
2
Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.Nek2 激酶信号在疟疾、骨骼、免疫和肾脏疾病向转移性癌症和耐药性的作用：Nek2 抑制剂开发的进展。
Molecules. 2022 Jan 6;27(2):347. doi: 10.3390/molecules27020347.
3
PD-1 Blockade in Classic Hodgkin Lymphoma.经典型霍奇金淋巴瘤中的程序性死亡受体1阻断疗法
JCO Oncol Pract. 2021 Feb;17(2):72-73. doi: 10.1200/OP.20.01020. Epub 2021 Jan 13.
4
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.帕博利珠单抗联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（KEYNOTE-183）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
5
How I treat myeloma with new agents.我如何用新药治疗骨髓瘤。
Blood. 2017 Sep 28;130(13):1507-1513. doi: 10.1182/blood-2017-05-743203. Epub 2017 Jul 26.
6
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.纳武利尤单抗治疗复发或难治性血液系统恶性肿瘤患者：Ib期研究的初步结果
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
7
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.埃罗妥珠单抗联合来那度胺和地塞米松治疗复发多发性骨髓瘤患者：随机、开放标签、1b-2期剂量递增研究的最终2期结果
Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.
8
Targeting the bone marrow microenvironment in multiple myeloma.靶向多发性骨髓瘤中的骨髓微环境。
Immunol Rev. 2015 Jan;263(1):160-72. doi: 10.1111/imr.12233.
9
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.NEK2 主要通过激活外排药物泵诱导耐药性，与骨髓瘤和其他癌症的不良预后相关。
Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001.
10
The Nek2 protein kinase: a novel regulator of centrosome structure.Nek2蛋白激酶：一种新型的中心体结构调节因子。
Oncogene. 2002 Sep 9;21(40):6184-94. doi: 10.1038/sj.onc.1205711.
Zotero 插件